Biostax (BTAX) 10-Q 20 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 20, 2019
Document And Entity Information
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	0001559356
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		445,577,799
Trading Symbol	IMUN
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 5,688	$ 5,859
Inventories	82,801	82,801
Total current assets	88,489	88,660
Fixed Assets:
Computer equipment, net of accumulated depreciation of $10,865 and $10,477 respectively	2,378	2,766
Deposits	200	200
Total assets	91,067	91,626
Current Liabilities:
Accounts payable	2,021,931	2,065,476
Accrued liabilities	3,605,755	3,302,355
Notes payable, net of debt discount	5,479,385	5,187,727
Derivative liability	738,609	786,706
Total current liabilities	11,845,680	11,342,264
Total liabilities	11,845,680	11,342,264
Commitments and Contingencies (Note 11)
Stockholders' Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 445,577,799 and 434,322,574 shares issued and outstanding respectively	45,558	43,433
Additional paid in capital	370,084,346	369,881,037
Stock issuances due	35,303	35,303
Accumulated deficit	(389,919,820)	(381,210,411)
Deficit attributable to common stockholders	(11,754,613)	(11,250,638)
Total stockholders' deficit	(11,754,613)	(11,250,638)
Total liabilities and stockholders' deficit	$ 91,067	$ 91,626

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 10,865	$ 10,477
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	445,577,799	434,322,574
Common stock, shares outstanding	445,577,799	434,322,574

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenues, net		$ 65,013
Cost of products sold		33,172
Gross profit		31,841
Operating expenses:
Selling, general and administrative	486,585	638,228
Research and development expense		129,191
Stock issued for services G&A	120,000	252,244
Depreciation and amortization expense	387	433
Total operating expenses	606,972	1,020,096
Loss from operations	(606,972)	(988,255)
Other income (expense):
Interest expense	(115,209)	(220,461)
Gain on Derivative Liability Revaluation	12,772	494,814
Loss on settlement of debt		(18,036)
Total other income (expense)	(102,437)	256,317
Net loss	(709,409)	(731,938)
Net loss attributable to non-controlling interest		(121,285)
Net loss attributable to common shareholders	$ (709,409)	$ (610,653)
Basic loss per share to common shareholders	$ 0	$ 0
Weighted average number of shares outstanding	447,626,057	387,621,835

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity/ (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock To Be Issued [Member]	Prepaid Services [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2017	$ 38,679	$ 366,625,144	$ 103,226	$ (226,667)	$ (373,035,183)	$ (4,608,585)	$ (11,103,386)
Balance, shares at Dec. 31, 2017	386,782,473
Issuance of common stock for prepaid services	$ 1,698	612,053	(67,923)				545,828
Issuance of common stock for prepaid services, shares	16,988,640
Amortization of prepaid services				226,667			226,667
Issuance of common stock for interest expense	$ 121	8,980					9,101
Issuance of common stock for interest expense, shares	200,000
Issuance of common stock in exchange for debt	$ 3,035	668,652					671,597
Issuance of common stock in exchange for debt, shares	30,351,461
Issuance of Cytocom common stock for cash and exercise of warrants		240,500					240,500
Issuance and modification of common stock warrants		1,725,798					1,725,798
Deconsolidation of Cytocom						5,058,967	5,058,967
Net loss					(8,175,228)	(450,382)	(8,625,610)
Balance at Dec. 31, 2018	$ 43,433	369,881,037	35,303		(381,210,411)		(11,250,638)
Balance, shares at Dec. 31, 2018	434,322,574
Issuance of common stock for prepaid services	$ 300	119,700					120,000
Issuance of common stock for prepaid services, shares	3,000,000
Amortization of prepaid services							0
Issuance of common stock in exchange for debt	$ 1,825	60,609					62,434
Issuance of common stock in exchange for debt, shares	18,255,225
Issuance of warrants in connection with debt agreement		23,000					23,000
Net loss					(709,409)		(709,409)
Balance at Mar. 31, 2019	$ 45,558	$ 370,084,346	$ 35,303		$ (381,919,820)		$ (11,754,613)
Balance, shares at Mar. 31, 2019	455,577,799

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (709,409)	$ (731,938)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	387	434
Amortization of debt discount	61,271	100,318
Amortization of stock issued for prepaid services		125,000
Stock issued for services	120,000	127,243
Change in value of derivative	(12,772)	(494,814)
Loss on settlement of debt		18,036
Stock issued for origination fees and interest expense		6,000
Expenses paid by lender		54,661
Changes in operating assets and liabilities:
Inventories	0	19,450
Accounts payable	210,933	78,199
Accrued liabilities	303,400	241,595
Net cash used in operating activities	(171)	(455,816)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of computer equipment		(1,971)
Net cash used in investing activities		(1,971)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock and exercise of warrants		50,000
Proceeds from issuance of notes payable		423,470
Net cash provided by financing activities		473,470
Net increase/(decrease) in cash and cash equivalents	(171)	15,683
Cash and cash equivalents at beginning of period	5,859	14,718
Cash and cash equivalents at end of period	5,688	30,401
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	16,000	15,210
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Debt discount	23,000	125,000
Accrue shares to be issued for debt and accrued interest		108,216
Conversion of debt and accrued interest to common stock	27,110
Settlement of derivative liability		243,199
Reclassification from accounts payable to notes payable	254,479
Reclassification from debt to accounts payable		17,284
Debt settled and reclassed to accrued expenses	35,325
Loss on debt conversion		$ 18,036

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Immune Therapeutics, Inc. (the “Company,” “we,” or “our”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc. The Company currently operates out of Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally. In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products. In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available. In December 2013, the Company formed a subsidiary, Cytocom Inc. (“Cytocom”), to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom to its shareholders. As part of the transaction (“Original Agreement”), the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On December 8, 2014, the number of Cytocom shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the Original Agreement, Cytocom issued an additional 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% stake in Cytocom on that date. In April 2016, the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock. Cytocom effectuated and finalized the reverse split in June 2016. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. In addition, the Company has been granted the rights to distribute and market Lodonal™ and MENK for animal use in the United States. The royalty due to Cytocom has been reduced from 5% to 1% of sales and the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement. Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis. The Restated Agreement was a condition of the Stock Agreement. At December 31, 2018, the Company’s equity interest in Cytocom stood at 15.5% of Cytocom’s common stock issued and outstanding on that date. The Company’s policies with respect to accounting for its equity interest in Cytocom is described in Note 2 to the “Notes to the Condensed Consolidated Financial Statements” below (“Summary of Significant Accounting Policies: Non-Controlling Interest in Consolidated Subsidiaries”). In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere. At present, the Company is a late development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for humans in Africa, Central and South America, the Caribbean and China (hereinafter referred to as “Emerging Markets”) and worldwide for animals and companion pet therapeutics. The Company is not permitted to market its licensed products in the United States. Going Concern The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at March 31, 2019 was not sufficient to meet the cash requirements to fund planned operations through for the next 12 months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. The Company experienced a net loss attributable to common shareholders of $709,409 and used cash and cash equivalents for operations in the amount of $171 during the quarter ended March 31, 2019, resulting in stockholders’ deficit of $11,754,613 at that date.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2018 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2018. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Non-Controlling Interest in Consolidated Subsidiaries Prior to May 1, 2018, the Company consolidated Cytocom. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc., in accordance with which the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement”). Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis on June 4, 2018. At March 31, 2019, the Company’s equity interest in Cytocom stood at 15.5% of Cytocom’s common stock issued and outstanding. Accordingly, the Company deconsolidated Cytocom as of May 1, 2018, and accounts for its retained interest in Cytocom under the equity method of accounting, with the Company’s share of Cytocom’s earnings recorded in “loss from equity method investment” in the consolidated statements of operations. As the balance of the Company’s investment in Cytocom has been $0 since December 31, 2018, no losses have been recognized during the quarter ended March 31, 2019. Revenue Recognition We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory. Sales of Lodonal TM Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and ‘the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). On January 1, 2019, the Company applied ASU 842 on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. At March 31, 2019, we had no leases that fall within the scope of this standard. Accordingly, the standard has no impact on our consolidated financial position or our results of operations. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value . Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At March 31, 2019, the Company has no cash balances in excess of insured limits. Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. Derivative Financial Instruments FASB ASC 820, Fair Value Measurements Inventory Inventories comprise finished product, raw materials and materials used for packaging. Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Inventory used in marketing activities is charged to selling, general and administrative expense. Inventory as of March 31, 2019 was valued at $82,801, a decrease of $95,297 or 54% from the inventory balance at the end of March 2018. Inventory at March 31, 2019 was made up primarily of finished pills and related packaging materials. The year-over-year decrease in inventory was due to the shipments of pills during 2018 to Nigeria and to pills used as samples. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the periods ended March 31, 2019 and March 31, 2018 was $387 and $433, respectively. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of March 31, 2019 and 2018, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2019, and 2018, the Company has not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position The Company’s potential dilutive securities which include warrants (as described in Note 8 to the Financial Statements – “Capital Structure – Common Stock and Common Stock Purchase Warrants”) and convertible debt (as described in Note 6 to the Financial Statements – “Notes Payable”), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: March 31, 2019 March 31, 2018 Common Stock Purchase Warrants 282,358,856 126,670,720 Convertible Debt 112,943,167 23,611,111 Recent Accounting Standards During the quarter ended March 31, 2019, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2019
Fixed Assets:
Fixed Assets	3. Fixed Assets March 31, 2019 December 31, 2018 Fixed Assets: $ $ Computer equipment 13,213 13,213 Less accumulated depreciation (10,835 ) (10,477 ) Fixed assets, net $ 2,378 $ 2,766 The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

Investments_ Deconsolidation of

Investments: Deconsolidation of Cytocom	3 Months Ended
	Mar. 31, 2019
Investments Deconsolidation Of Cytocom
Investments: Deconsolidation of Cytocom	4. Investments: Deconsolidation of Cytocom In accordance with the May 1, 2018 “Restated Agreement” with Cytocom, the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. Accordingly, effective May 1, 2018, the Company deconsolidated Cytocom. However, the Company exercises influence through its retained equity interest and through representation on Cytocom’s board of directors. As a result, the Company uses the equity method to account for its retained interest in Cytocom On May 1, 2018, the Company recorded an equity method investment in Cytocom of $1,189, the par value of Cytocom common stock multiplied by the number of shares owned by the Company, due to the negative equity associated with Cytocom’s underlying financial position. As a result of the continuing losses in Cytocom, the balance of this investment is currently $0. At March 31, 2019, Cytocom had no significant assets or income.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Accrued Liabilities	5. Accrued Liabilities Accrued expenses and other liabilities consist of the following: March 31, 2019 December 31, 2018 Accrued payroll to officers and others 2,582,839 2,010,570 Accrued interest and penalties – notes payable 886,859 877,571 Estimated legal settlements 136,057 136,057 Other accrued liabilities - 15,512 Derivative Liability 738,609 786,706 Total accrued expenses and other liabilities $ 4,344,364 $ 3,826,416

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	6. Notes payable Notes payable consist of the following: March 31, 2019 December 31, 2018 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. As of March 31, 2019, the note is in default. The note earns interest at a rate of 18% per annum. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at March 31, 2019, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016 and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $375,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $100,000, interest is payable in a fixed amount not tied to a specific interest rate. The Company was unable to repay the notes at maturity and at March 31, 2019 the note was in default. 725,994 725,994 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at March 31, 2019 the note was in default. 97,737 97,737 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at March 31, 2019 the notes were in default. 206,000 206,000 Notes aggregating $1,350,000 issued in the fourth quarter 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As March 31, 2019, the notes were in default. 1,354,000 1,354,000 Notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018. At March 31, 2019, the notes were in default. 500,000 500,000 Promissory notes issued January 25, 2017. The lenders earn interest at 7% per month. The notes mature on July 5, 2017, and at March 31, 2019 the notes were in default. 50,000 50,000 Notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At March 31, 2019, the notes were in default. 300,000 300,000 Notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At March 31, 2019, the notes were in default. 191,800 191,800 Promissory note from $425,000 was issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock using the lowest value of the Company’s common stock 25 days prior to the conversion. In 2018, The defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at March 31, 2019 had increased to $454,032 $27,110 of accrued interest owed on the note has been converted to stock. The Company has accrued a $738,609 derivative liability for the remaining conversion right. 454,032 455,122 Notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum. At March 31, 2019, the notes were in default. 105,500 105,500 Notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At March 31, 2019, These notes were in default 47,975 47,975 Notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000,000 and 20,000,000 shares with an exercise price of $0.0005. At March 31, 2019 the notes were in default 125,000 125,000 Notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest between 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000,000 and 5,000,000 shares with an exercise price of $0.005. At March 31, 2019 the notes were in default 65,000 65,000 Notes aggregating $193,000 issued in the third quarter of 2018. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600,000 and 5,000,000 shares with an exercise price of $0.005. At March 31, 2019. $103,000 of these notes were in default 193,000 193,000 Notes aggregating $533,855 issued in the fourth quarter of 2018. The notes accrue interest from 2% to 3.5% per annum and mature between February 2019 and December 2019. These notes include warrants between 200,000 and 39,500,000 shares with an exercise price of $0.005 to $0.04 At March 31, 2019. $379,000 of these notes were in default 533,855 533,855 Notes aggregating $23,000 issued in the first quarter of 2019. The notes accrue interest at 2% per annum and mature during July 2019. These notes include warrants between 4,600,000 shares with an exercise price of $0.005. 23,000 - Notes aggregating $231,478 issued in the first quarter of 2019. The notes accrue interest at 6% per annum and mature in February 2020. 231,478 - Less: Original issue discount on notes payable and warrants issued with notes. (110,986 ) (149,256 ) Total $ 5,479,385 $ 5,187,727 As of March 31, 2019, the Company had accrued $877,570 in unpaid interest and default penalties. During the quarter ended March 31, 2019, 18,255,225 shares with a fair value of $78,500 were issued by the Company for settlement of promissory notes totaling $27,710.

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	7 Derivative Liabilities As of March 31, 2019, and December 31, 2018 the aggregate fair value of the outstanding derivative liability was $738,609 and $786,706, respectively. The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumption during the quarter March 31, 2019: Three months ended March 31, 2019 Volatility 295.00 % Risk-free interest rate 2.40 % Expected dividends - % Expected term 1 year The Company determines the fair values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three levels of inputs may be used to measure fair value: Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses Level 3 inputs to estimate the fair value of its derivative liabilities. The following schedule summarizes the valuation of financial instruments at fair value in the balance sheet as of March 31, 2019: Fair Value Measurements as of March 31, 2019 Level 1 Level 2 Level 3 Assets Total assets - - - Liabilities Conversion option derivative liability $ - $ - $ 738,609 Total liabilities $ - $ - $ 738,609 The following table set forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Unobservable Input (Level 3) Beginning balance $ 786,706 Change in fair value (12,772 ) Partial settlements of liability (35,325 ) Ending balance $ 738,609

Capital Structure - Common Stoc

Capital Structure - Common Stock and Stock Purchase Warrants	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Capital Structure - Common Stock and Stock Purchase Warrants	8 Capital Structure – Common Stock and Stock Purchase Warrants , Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of March 31, 2019, and 2018, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share. As of March 31, 2019, the Company had 455,577,799 shares of common stock outstanding and 434,322,574 outstanding as of December 31, 2018. Stock Warrants In the quarter ended March 31, 2019, 4,600,000 new warrants were issued by the Company. There were no modifications of the terms of any warrants issued by the Company in the quarter ended March 31, 2019 and 2018. Following is a summary of outstanding stock warrants at March 31, 2019 and activity during the three months ended: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2018 281,782,856 $ 0.001-3.74 $ 0.09 Issued in 2019 4,600,000 $ .005-.005 $ .01 Expired and forfeited (4,024,000 ) $ 0.-2.00 $ 1.25 Exercised - $ 0 $ 0 Warrants as of March 31, 2019 282,358,856 $ .001-3.74 $ 0.07 Summary of outstanding warrants as of March 31, 2019: Expiration Date Number of Shares Exercise Price Remaining Life (years) Second Quarter 2019 135,000 $ 0.50-2.00 0.25 Third Quarter 2019 260,000 $ 0.07-0.23 0.50 Fourth Quarter 2019 23,222,726 $ 0.50-1.50 0.75 Second Quarter 2020 300,000 $ 0.50 1.25 Fourth Quarter 2020 1,000,000 $ 0.20 1.75 First Quarter 2021 12,600,000 $ 0.20 2.00 Second Quarter 2021 5,812,252 $ 0.01408-0.20 2.25 Third Quarter 2021 5,166,667 $ 0.03-0.20 2.50 Fourth Quarter 2021 300,000 $ 0.10 2.75 Second Quarter 2022 1,750,000 $ 0.15 3.25 Third Quarter 2022 2,650,000 $ 0.05-0.10 3.50 Fourth Quarter 2022 9,811,422 $ 0.08-0.29 3.75 First Quarter 2023 8,000,000 $ 0.005-0.04 4.00 Second Quarter 2023 15,000,000 $ 0.005-0.20 4.25 Third Quarter 2023 76,700,000 $ 0.005-0.10 4.50 Fourth Quarter 2023 60,243,000 $ 0.005 4.75 First Quarter 2024 34,600,000 $ 0.005 5.00 Third Quarter 2028 3,000,000 $ 0.07 9.50 Second Quarter 2032 21,807,789 $ 0.01-.0679 13.25 282,358,856 $ 0.005-15.00

Stock Compensation

Stock Compensation	3 Months Ended
	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Compensation	9 Stock Compensation Shares Issued for Services During the periods ended March 31, 2019 and 2018, the Company issued 3,000,000 and 2,863,640 shares of common stock respectively for consulting fees. The Company valued these shares at $120,000 and $198,477 respectively, based upon the fair value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods, which are typically between 12 and 24 months. The amortization of prepaid services totaled $0 and $125,000 for the quarters ended March 31, 2019 and 2018.

Income Taxes - Results of Opera

Income Taxes - Results of Operations	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes - Results of Operations	10. Income Taxes – Results of Operations There was no income tax expense reflected in the results of operations for the years ended March 31, 2019 and 2018 because the Company incurred a net loss in both years. On December 22, 2018, the President of the United States signed the Tax Cuts and Jobs Act (“U.S. Tax Reform”), which enacts a wide range of changes to the U.S. corporate income tax system. The impact of U.S. Tax Reform primarily represents the Company’s estimates of revaluing the Company’s U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%, effective for the 2018 tax year. The Company has recognized no tax benefit for the losses generated for the periods through March 31, 2019. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided. Our effective tax rate for fiscal years 2019 and 2018 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year but are not consistent from year to year.

Licenses and Supply Agreements

Licenses and Supply Agreements	3 Months Ended
	Mar. 31, 2019
Licenses And Supply Agreements
Licenses and Supply Agreements	11. Licenses and Supply Agreements Patent and Subsidiary Acquisition In December 2014, the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. Cytocom licensed back to the Company a perpetual, non-exclusive, royalty-free right and license to use the assigned intellectual property for veterinary indications and for the marketing rights to emerging markets, access to all clinical data, use of the formulation for LDN and MENK. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. In addition, the Company has been granted the rights to distribute and market Lodonal™ and MENK for animal use in the United States. The royalty due to Cytocom has been reduced from 5% to 1% of sales and the Company no longer has any ongoing obligations to pay for the cost in connection with the assets of Cytocom.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Distribution Agreements in Nigeria In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The first deliveries under the agreement took place in February 2018. Under the original agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment. Due to the fact that AHAR Pharma failed to meet its contractual purchase obligations, the Company formally issued notice of default under the agreement. On April 18, 2018, AHAR Pharma transferred its rights under the Distribution Agreement to Fidson Healthcare Plc (“Fidson”), and Fidson signed an exclusive distribution agreement with the Company to distribute Lodonal™. There were no shipments under this agreement in the first quarter of 2019. Agreements with Hubei Qianjiang Pharmaceutical Company On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (“Qianjiang Pharmaceutical”), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the “Venture Agreement”) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China. The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account. On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine – Enkephalin Cooperation (the “Amendment”) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China and agreed to immediately initiate three-month Good Laboratory Practice (“GLP”) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA. In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Company’s licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fess, duration and termination therein. In December of 2016 Qianjiang Pharmaceutical delivered various documents under the agreements related to its studies of Exploratory Toxicology (nGLP) and Definitive Toxicology (GLP). In addition to the pharmacology and toxicology studies, Qianjiang Pharmaceutical and China Peptide completed the formulation and CMC necessary to scale up manufacturing of MENK. There has been no progress under the agreements in the past 12 months, since a change of ownership of Qianjiang Pharmaceutical in 2017. The Company continues to hold discussions with new management about the future of the agreements. Contract Manufacturing Agreements On October 25, 2016, the Company and Acromax Dominicana, SA (“Acromax”), which is based in the Dominican Republic, entered into a contract for manufacturing of LDN tablets, capsules and/or creams (“Agreement”). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms. Operating Leases At March 31, 2019, the Company was a party to an agreement to lease office space in Orlando, Florida. Rental expense for the three months ended March 31, 2019 and 2018 was $5,282 and $4,281 respectively.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On April 8, 2019, the Company signed a second amendment to its licensing agreement (the “Second Amendment”) with Cytocom. The Second Amendment confirmed that, as of its effective date (December 31, 2018), the Company owned 15.57% of the common shares issued and outstanding on that date. The Company agreed to assume the obligation to repay all accounts payable obligations and accrued liabilities owed by Cytocom as of the effective date, except those accounts payable obligations and accrued liabilities as specified in the Second Amendment. The Company also assumed the obligation to repay all notes payable, together with any interest or fees payable thereon, owed by Cytocom as of the effective date, except those notes payable obligations, together with any interest or fees payable thereon, as specified in the Second Amendment. The parties further agreed that in the event of a change of control of Cytocom, and at the option of Cytocom, the Company would have the right to purchase outright the Company’s licensing rights to Emerging Markets for humans under the License Agreement at a price equal to the value of those licensing rights as determined by an independent valuator acceptable to the Company and Cytocom.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2018 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2018. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
Non-Controlling Interest in Consolidated Subsidiaries	Non-Controlling Interest in Consolidated Subsidiaries Prior to May 1, 2018, the Company consolidated Cytocom. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc., in accordance with which the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement”). Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis on June 4, 2018. At March 31, 2019, the Company’s equity interest in Cytocom stood at 15.5% of Cytocom’s common stock issued and outstanding. Accordingly, the Company deconsolidated Cytocom as of May 1, 2018, and accounts for its retained interest in Cytocom under the equity method of accounting, with the Company’s share of Cytocom’s earnings recorded in “loss from equity method investment” in the consolidated statements of operations. As the balance of the Company’s investment in Cytocom has been $0 since December 31, 2018, no losses have been recognized during the quarter ended March 31, 2019.
Revenue Recognition	Revenue Recognition We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory. Sales of Lodonal TM
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and ‘the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). On January 1, 2019, the Company applied ASU 842 on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. At March 31, 2019, we had no leases that fall within the scope of this standard. Accordingly, the standard has no impact on our consolidated financial position or our results of operations.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value .
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At March 31, 2019, the Company has no cash balances in excess of insured limits.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Derivative Financial Instruments	Derivative Financial Instruments FASB ASC 820, Fair Value Measurements
Inventory	Inventory Inventories comprise finished product, raw materials and materials used for packaging. Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Inventory used in marketing activities is charged to selling, general and administrative expense. Inventory as of March 31, 2019 was valued at $82,801, a decrease of $95,297 or 54% from the inventory balance at the end of March 2018. Inventory at March 31, 2019 was made up primarily of finished pills and related packaging materials. The year-over-year decrease in inventory was due to the shipments of pills during 2018 to Nigeria and to pills used as samples.
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the periods ended March 31, 2019 and March 31, 2018 was $387 and $433, respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of March 31, 2019 and 2018, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2019, and 2018, the Company has not accrued any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.
Net Loss Per Share of Common Stock	Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position The Company’s potential dilutive securities which include warrants (as described in Note 8 to the Financial Statements – “Capital Structure – Common Stock and Common Stock Purchase Warrants”) and convertible debt (as described in Note 6 to the Financial Statements – “Notes Payable”), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: March 31, 2019 March 31, 2018 Common Stock Purchase Warrants 282,358,856 126,670,720 Convertible Debt 112,943,167 23,611,111
Recent Accounting Standards	Recent Accounting Standards During the quarter ended March 31, 2019, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of Antidilutive Securities	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: March 31, 2019 March 31, 2018 Common Stock Purchase Warrants 282,358,856 126,670,720 Convertible Debt 112,943,167 23,611,111

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2019
Fixed Assets:
Schedule of Fixed Assets	March 31, 2019 December 31, 2018 Fixed Assets: $ $ Computer equipment 13,213 13,213 Less accumulated depreciation (10,835 ) (10,477 ) Fixed assets, net $ 2,378 $ 2,766

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses and other liabilities consist of the following: March 31, 2019 December 31, 2018 Accrued payroll to officers and others 2,582,839 2,010,570 Accrued interest and penalties – notes payable 886,859 877,571 Estimated legal settlements 136,057 136,057 Other accrued liabilities - 15,512 Derivative Liability 738,609 786,706 Total accrued expenses and other liabilities $ 4,344,364 $ 3,826,416

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consist of the following: March 31, 2019 December 31, 2018 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. As of March 31, 2019, the note is in default. The note earns interest at a rate of 18% per annum. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at March 31, 2019, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016 and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $375,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $100,000, interest is payable in a fixed amount not tied to a specific interest rate. The Company was unable to repay the notes at maturity and at March 31, 2019 the note was in default. 725,994 725,994 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at March 31, 2019 the note was in default. 97,737 97,737 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at March 31, 2019 the notes were in default. 206,000 206,000 Notes aggregating $1,350,000 issued in the fourth quarter 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As March 31, 2019, the notes were in default. 1,354,000 1,354,000 Notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018. At March 31, 2019, the notes were in default. 500,000 500,000 Promissory notes issued January 25, 2017. The lenders earn interest at 7% per month. The notes mature on July 5, 2017, and at March 31, 2019 the notes were in default. 50,000 50,000 Notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At March 31, 2019, the notes were in default. 300,000 300,000 Notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At March 31, 2019, the notes were in default. 191,800 191,800 Promissory note from $425,000 was issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock using the lowest value of the Company’s common stock 25 days prior to the conversion. In 2018, The defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at March 31, 2019 had increased to $454,032 $27,110 of accrued interest owed on the note has been converted to stock. The Company has accrued a $738,609 derivative liability for the remaining conversion right. 454,032 455,122 Notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum. At March 31, 2019, the notes were in default. 105,500 105,500 Notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At March 31, 2019, These notes were in default 47,975 47,975 Notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000,000 and 20,000,000 shares with an exercise price of $0.0005. At March 31, 2019 the notes were in default 125,000 125,000 Notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest between 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000,000 and 5,000,000 shares with an exercise price of $0.005. At March 31, 2019 the notes were in default 65,000 65,000 Notes aggregating $193,000 issued in the third quarter of 2018. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600,000 and 5,000,000 shares with an exercise price of $0.005. At March 31, 2019. $103,000 of these notes were in default 193,000 193,000 Notes aggregating $533,855 issued in the fourth quarter of 2018. The notes accrue interest from 2% to 3.5% per annum and mature between February 2019 and December 2019. These notes include warrants between 200,000 and 39,500,000 shares with an exercise price of $0.005 to $0.04 At March 31, 2019. $379,000 of these notes were in default 533,855 533,855 Notes aggregating $23,000 issued in the first quarter of 2019. The notes accrue interest at 2% per annum and mature during July 2019. These notes include warrants between 4,600,000 shares with an exercise price of $0.005. 23,000 - Notes aggregating $231,478 issued in the first quarter of 2019. The notes accrue interest at 6% per annum and mature in February 2020. 231,478 - Less: Original issue discount on notes payable and warrants issued with notes. (110,986 ) (149,256 ) Total $ 5,479,385 $ 5,187,727

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions	The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumption during the quarter March 31, 2019: Three months ended March 31, 2019 Volatility 295.00 % Risk-free interest rate 2.40 % Expected dividends - % Expected term 1 year
Schedule of Valuation of Financial Instruments	The following schedule summarizes the valuation of financial instruments at fair value in the balance sheet as of March 31, 2019: Fair Value Measurements as of March 31, 2019 Level 1 Level 2 Level 3 Assets Total assets - - - Liabilities Conversion option derivative liability $ - $ - $ 738,609 Total liabilities $ - $ - $ 738,609
Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities	The following table set forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Unobservable Input (Level 3) Beginning balance $ 786,706 Change in fair value (12,772 ) Partial settlements of liability (35,325 ) Ending balance $ 738,609

Capital Structure - Common St_2

Capital Structure - Common Stock and Stock Purchase Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants at March 31, 2019 and activity during the three months ended: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2018 281,782,856 $ 0.001-3.74 $ 0.09 Issued in 2019 4,600,000 $ .005-.005 $ .01 Expired and forfeited (4,024,000 ) $ 0.-2.00 $ 1.25 Exercised - $ 0 $ 0 Warrants as of March 31, 2019 282,358,856 $ .001-3.74 $ 0.07
Summary of Outstanding Warrants	Summary of outstanding warrants as of March 31, 2019: Expiration Date Number of Shares Exercise Price Remaining Life (years) Second Quarter 2019 135,000 $ 0.50-2.00 0.25 Third Quarter 2019 260,000 $ 0.07-0.23 0.50 Fourth Quarter 2019 23,222,726 $ 0.50-1.50 0.75 Second Quarter 2020 300,000 $ 0.50 1.25 Fourth Quarter 2020 1,000,000 $ 0.20 1.75 First Quarter 2021 12,600,000 $ 0.20 2.00 Second Quarter 2021 5,812,252 $ 0.01408-0.20 2.25 Third Quarter 2021 5,166,667 $ 0.03-0.20 2.50 Fourth Quarter 2021 300,000 $ 0.10 2.75 Second Quarter 2022 1,750,000 $ 0.15 3.25 Third Quarter 2022 2,650,000 $ 0.05-0.10 3.50 Fourth Quarter 2022 9,811,422 $ 0.08-0.29 3.75 First Quarter 2023 8,000,000 $ 0.005-0.04 4.00 Second Quarter 2023 15,000,000 $ 0.005-0.20 4.25 Third Quarter 2023 76,700,000 $ 0.005-0.10 4.50 Fourth Quarter 2023 60,243,000 $ 0.005 4.75 First Quarter 2024 34,600,000 $ 0.005 5.00 Third Quarter 2028 3,000,000 $ 0.07 9.50 Second Quarter 2032 21,807,789 $ 0.01-.0679 13.25 282,358,856 $ 0.005-15.00

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)	Jun. 04, 2018	May 01, 2018	Dec. 08, 2014	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Net loss attributable to common shareholders						$ 709,409	$ 610,653
Cash and cash equivalents used in operating activities						171	$ 455,816
Stockholder's deficit						$ 11,754,613		$ 11,250,638	$ 11,103,386
Cytocom Inc., [Member]
Ownership percentage						15.50%		15.50%
Cytocom Inc., [Member]
Royalty percentage				5.00%
Amount of debt converted into common stock	$ 4,000,000
Percentage of common stock issued in exchange of debt	10.00%
Cytocom Inc., [Member] | Minimum [Member]
Royalty percentage		1.00%
Cytocom Inc., [Member] | Maximum [Member]
Royalty percentage		5.00%
Cytocom Inc., [Member] | Original Agreement [Member]
Number of common stock issued			140,100,000
Ownership percentage			55.30%
Cytocom Inc., [Member] | Shareholders [Member]
Number of common stock issued			113,242,522
Irish Limited Liability [Member]
Percentage of low corporate income tax rate					12.50%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Jun. 04, 2018USD ($)	Mar. 31, 2019USD ($)Segment	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)
Maximum of annual gross revenue				$ 1,000,000,000
Federal deposit insurance corporation value		$ 250,000
Number of operating segment | Segment		1
Inventory		$ 82,801		$ 82,801
Decrease in inventory		$ 0	$ (19,450)
Percentage on decrease in inventory		54.00%
Depreciation expense		$ 387	434
Accrued interest or penalties related to uncertain tax positions
Property and Equipment [Member] | Minimum [Member]
Property and equipment useful lives		3 years
Property and Equipment [Member] | Maximum [Member]
Property and equipment useful lives		5 years
Cytocom Inc., [Member]
Percentage of equity ownership		15.50%		15.50%
Cytocom Inc., [Member]
Amount of debt converted into common stock	$ 4,000,000
Percentage of common stock issued in exchange of debt	10.00%
Investment				$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Common Stock Purchase Warrants [Member]
Potentially dilutive securities	282,358,856	126,670,720
Convertible Debt [Member]
Potentially dilutive securities	112,943,167	23,611,111

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Fixed Assets:
Computer equipment	$ 13,213	$ 13,213
Less accumulated depreciation	(10,865)	(10,477)
Fixed assets, net	$ 2,378	$ 2,766

Investments_ Deconsolidation _2

Investments: Deconsolidation of Cytocom (Details Narrative) - Cytocom Inc., [Member] - USD ($)	3 Months Ended
	Mar. 31, 2019	May 01, 2018
Equity method investments		$ 1,189
Loss on investment	$ 0

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued payroll to officers and others	$ 2,582,839	$ 2,010,570
Accrued interest and penalties - notes payable	886,859	877,571
Estimated legal settlements	136,057	136,057
Other accrued liabilities		15,512
Derivative Liability	738,609	786,706
Total accrued expenses and other liabilities	$ 4,344,364	$ 3,826,416

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Accrued unpaid interest and default penalties	$ 877,570
Issuance of common stock for conversion of debt	$ 62,434	$ 671,597
Promissory Notes [Member]
Issuance of common stock for conversion of debt, shares	18,255,225
Issuance of common stock for conversion of debt	$ 78,500
Settlement of promissory notes	$ 27,710

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018	Oct. 31, 2017
Total	$ 5,479,385	$ 5,187,727
Less: Original issue discounts on notes payable and warrants issued with notes	(110,986)	(149,256)
Notes Payable One [Member]
Total	100,000	100,000
Notes Payable Two [Member]
Total	286,000	286,000
Notes Payable Three [Member]
Total	725,994	725,994
Notes Payable Four [Member]
Total	97,737	97,737
Notes Payable Five [Member]
Total	206,000	206,000
Notes Payable Six [Member]
Total	1,354,000	1,354,000
Notes Payable Seven [Member]
Total	500,000	500,000
Notes Payable Eight [Member]
Total	50,000	50,000
Notes Payable Nine [Member]
Total	300,000	300,000
Notes Payable Ten [Member]
Total	191,800	191,800
Notes Payable Eleven [Member]
Total	454,032	455,122
Less: Original issue discounts on notes payable and warrants issued with notes			$ (70,000)
Notes Payable Twelve [Member]
Total	105,500	105,500
Notes Payable Thirteen [Member]
Total	47,975	47,975
Notes Payable Fourteen [Member]
Total	125,000	125,000
Notes Payable Fifteen [Member]
Total	65,000	65,000
Notes Payable Sixteen [Member]
Total	193,000	193,000
Notes Payable Seventeen [Member]
Total	533,855	533,855
Notes Payable Eighteen [Member]
Total	23,000
Notes Payable Nineteen [Member]
Total	$ 231,478

Notes Payable - Schedule of N_2

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)

Jan. 25, 2017

Nov. 03, 2015

Jul. 29, 2014

Mar. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Sep. 30, 2018USD ($)$ / sharesshares

Jun. 30, 2018USD ($)$ / sharesshares

Mar. 31, 2018USD ($)$ / sharesshares

Sep. 30, 2017USD ($)

Jun. 30, 2017USD ($)

Mar. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)Installments

Dec. 31, 2016USD ($)

Dec. 31, 2017USD ($)

Oct. 31, 2017USD ($)

Accrued interest

$ 886,859

$ 877,571

Original issuance discount

110,986

$ 149,256

Notes Payable Two [Member]

Percentage of interest rate per annum

10.00%

Number of installments, months | Installments

36

Notes Payable Two [Member] | Maximum [Member]

Maximum amount raise in debt

$ 2,000,000

Notes Payable Four [Member]

Note matures date

Nov. 3, 2016

Percentage of interest rate per annum

10.00%

Notes Payable Five [Member] | Lenders [Member]

Note matures date

Dec. 31, 2017

Percentage of interest rate per annum

2.00%

2.00%

2.00%

Notes Payable Six [Member]

Percentage of interest rate per annum

2.00%

2.00%

2.00%

Debt instrument maturity date description

November 1, 2017 and December 31, 2017

Notes aggregating default amount

$ 1,350,000

$ 1,350,000

$ 1,350,000

Notes Payable Seven [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

January 12, 2018 and March 31, 2018

Notes aggregating default amount

$ 500,000

Notes Payable Nine [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

April 3, 2018 and May 31, 2018

Notes aggregating default amount

$ 300,000

Notes Payable Ten [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

June 16, 2018 and December 31, 2018

Notes aggregating default amount

$ 191,800

Notes Payable Eleven [Member]

Maximum amount raise in debt

454,032

Accrued interest

27,110

Notes aggregating default amount

$ 425,000

Original issuance discount

$ 70,000

Derivative liability

738,609

Notes Payable Twelve [Member]

Percentage of interest rate per annum

2.00%

Notes aggregating default amount

$ 105,500

Notes Payable Thirteen [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

May 2018 and January 2019

Notes aggregating default amount

$ 47,975

Notes Payable Fourteen [Member]

Debt instrument maturity date description

April 2018 and June 2018

Notes aggregating default amount

$ 125,000

Warrant exercise price per share | $ / shares

$ 0.0005

Notes Payable Fourteen [Member] | Maximum [Member]

Percentage of interest rate per annum

12.00%

Number of warrants | shares

20,000,000

Notes Payable Fourteen [Member] | Minimum [Member]

Percentage of interest rate per annum

2.00%

Number of warrants | shares

5,000,000

Notes Payable Fifteen [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

July 2018 and October 2018

Notes aggregating default amount

$ 65,000

Warrant exercise price per share | $ / shares

$ 0.005

Notes Payable Fifteen [Member] | Maximum [Member]

Number of warrants | shares

5,000,000

Notes Payable Fifteen [Member] | Minimum [Member]

Number of warrants | shares

1,000,000

Notes Payable Sixteen [Member]

Percentage of interest rate per annum

2.00%

Debt instrument maturity date description

November 2018 and January 2019

Notes aggregating default amount

103,000

$ 193,000

Warrant exercise price per share | $ / shares

$ 0.005

Notes Payable Sixteen [Member] | Maximum [Member]

Number of warrants | shares

5,000,000

Notes Payable Sixteen [Member] | Minimum [Member]

Number of warrants | shares

600,000

Notes Payable Seventeen [Member]

Debt instrument maturity date description

February 2019 and December 2019

Notes aggregating default amount

$ 379,000

$ 533,855

Notes Payable Seventeen [Member] | Maximum [Member]

Percentage of interest rate per annum

3.50%

Number of warrants | shares

39,500,000

Warrant exercise price per share | $ / shares

$ 0.04

Notes Payable Seventeen [Member] | Minimum [Member]

Percentage of interest rate per annum

2.00%

Number of warrants | shares

200,000

Warrant exercise price per share | $ / shares

$ 0.005

Notes Payable Eighteen [Member]

Note matures date

Jul. 31, 2019

Percentage of interest rate per annum

2.00%

Notes aggregating default amount

$ 23,000

Number of warrants | shares

4,600,000

Warrant exercise price per share | $ / shares

$ 0.005

Notes Payable Nineteen [Member]

Note matures date

Feb. 29, 2020

Percentage of interest rate per annum

6.00%

Notes aggregating default amount

$ 231,478

Ira Gaines [Member] | Notes Payable One [Member]

Note matures date

Dec. 1, 2017

Percentage of interest rate per annum

18.00%

Lenders [Member] | Notes Payable Three [Member]

Debt instrument maturity date description

June 14, 2015 and December 1, 2017

Aggregating loan

375,994

375,994

$ 375,994

Accrued interest

$ 100,000

$ 100,000

$ 100,000

Lenders [Member] | Notes Payable Three [Member] | Maximum [Member]

Percentage of interest rate per annum

18.00%

18.00%

18.00%

Lenders [Member] | Notes Payable Three [Member] | Minimum [Member]

Percentage of interest rate per annum

2.00%

2.00%

2.00%

Lenders [Member] | Notes Payable Eight [Member]

Note matures date

Jul. 5, 2017

Percentage of interest rate per annum

7.00%

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities	$ 738,609	$ 786,706

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Estimated Fair Value of Derivative Liability Valuation Assumptions (Details) - Black-Scholes Option Pricing Model [Member]	3 Months Ended
	Mar. 31, 2019
Volatility [Member]
Fair value assumptions, measurement input, percentages	295.00%
Risk-Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	2.40%
Expected Dividends [Member]
Fair value assumptions, measurement input, percentages	0.00%
Expected Term [Member]
Fair value assumptions, measurement input, term	1 year

Derivative Liabilities - Sche_2

Derivative Liabilities - Schedule of Valuation of Financial Instruments (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Total assets	$ 91,067	$ 91,626
Total liabilities	11,845,680	$ 11,342,264
Level 1 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 2 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 3 [Member]
Total assets
Conversion option derivative liability	738,609
Total liabilities	$ 738,609

Derivative Liabilities - Sche_3

Derivative Liabilities - Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Derivative liabilities beginning balance	$ 786,706
Derivative liabilities ending balance	738,609
Level 3 [Member]
Derivative liabilities beginning balance	786,706
Change in fair value	(12,772)
Partial settlements of liability	(35,325)
Derivative liabilities ending balance	$ 786,706

Capital Structure - Common St_3

Capital Structure - Common Stock and Stock Purchase Warrants (Details Narrative) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Common stock, shares authorized	500,000,000	500,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares outstanding	445,577,799	434,322,574
Warrant [Member]
Number of warrants issued during period	4,600,000

Capital Structure - Common St_4

Capital Structure - Common Stock and Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Shares Warrants, Beginning balance | shares	281,782,856
Number of Shares Warrants, Issued | shares	4,600,000
Number of Shares Warrants, Expired and forfeited | shares	(4,024,000)
Number of Shares Warrants, Exercised | shares
Number of Shares Warrants, Ending balance | shares	282,358,856
Exercise Price, Exercised	$ 0
Weighted average price, Beginning balance	0.09
Weighted average price, Issued	.01
Weighted average price, Expired and forfeited	1.25
Weighted average price, Exercised	0
Weighted average price, Ending balance	0.07
Minimum [Member]
Exercise Price, Beginning balance	0.001
Exercise Price, Issued	.005
Exercise Price, Expired and forfeited	0
Exercise Price, Ending balance	.001
Maximum [Member]
Exercise Price, Beginning balance	3.74
Exercise Price, Issued	.005
Exercise Price, Expired and forfeited	2
Exercise Price, Ending balance	$ 3.74

Capital Structure - Common St_5

Capital Structure - Common Stock and Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Shares | shares	282,358,856
Exercise Price Lower Limit	$ 0.005
Exercise Price Upper Limit	$ 15
Second Quarter 2019 [Member]
Number of Shares | shares	135,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 2
Remaining Life (years)	2 months 30 days
Third Quarter 2019 [Member]
Number of Shares | shares	260,000
Exercise Price Lower Limit	$ 0.07
Exercise Price Upper Limit	$ 0.23
Remaining Life (years)	6 months
Fourth Quarter 2019 [Member]
Number of Shares | shares	23,222,726
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	9 months
Second Quarter 2020 [Member]
Number of Shares | shares	300,000
Exercise Price Upper Limit	$ 0.50
Remaining Life (years)	1 year 2 months 30 days
Fourth Quarter 2020 [Member]
Number of Shares | shares	1,000,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	1 year 9 months
First Quarter 2021 [Member]
Number of Shares | shares	12,600,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	2 years
Second Quarter 2021 [Member]
Number of Shares | shares	5,812,252
Exercise Price Lower Limit	$ 0.01408
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	2 years 2 months 30 days
Third Quarter 2021 [Member]
Number of Shares | shares	5,166,667
Exercise Price Lower Limit	$ 0.03
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	2 years 6 months
Fourth Quarter 2021 [Member]
Number of Shares | shares	300,000
Exercise Price Upper Limit	$ 0.10
Remaining Life (years)	2 years 9 months
Second Quarter 2022 [Member]
Number of Shares | shares	1,750,000
Exercise Price Upper Limit	$ 0.15
Remaining Life (years)	3 years 2 months 30 days
Third Quarter 2022 [Member]
Number of Shares | shares	2,650,000
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 0.10
Remaining Life (years)	3 years 6 months
Fourth Quarter 2022 [Member]
Number of Shares | shares	9,811,422
Exercise Price Lower Limit	$ 0.08
Exercise Price Upper Limit	$ 0.29
Remaining Life (years)	3 years 9 months
First Quarter 2023 [Member]
Number of Shares | shares	8,000,000
Exercise Price Lower Limit	$ 0.005
Exercise Price Upper Limit	$ 0.04
Remaining Life (years)	4 years
Second Quarter 2023 [Member]
Number of Shares | shares	15,000,000
Exercise Price Lower Limit	$ 0.005
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	4 years 2 months 30 days
Third Quarter 2023 [Member]
Number of Shares | shares	76,700,000
Exercise Price Lower Limit	$ 0.005
Exercise Price Upper Limit	$ 0.10
Remaining Life (years)	4 years 6 months
Fourth Quarter 2023 [Member]
Number of Shares | shares	60,243,000
Exercise Price Upper Limit	$ 0.005
Remaining Life (years)	4 years 9 months
First Quarter 2024 [Member]
Number of Shares | shares	34,600,000
Exercise Price Upper Limit	$ 0.005
Remaining Life (years)	5 years
Third Quarter 2028 [Member]
Number of Shares | shares	3,000,000
Exercise Price Upper Limit	$ 0.07
Remaining Life (years)	9 years 6 months
Second Quarter 2032 [Member]
Number of Shares | shares	21,807,789
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ .0679
Remaining Life (years)	13 years 2 months 30 days

Stock Compensation (Details Nar

Stock Compensation (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Number of common stock issued for services, value	$ 120,000	$ 198,477	$ 545,828
Amortization of prepaid services	$ 0	$ 125,000	$ 226,667
Minimum [Member]
Consulting fees amortized period	12 months
Maximum [Member]
Consulting fees amortized period	24 months
Common Stock [Member]
Number of common stock issued for services	3,000,000	2,863,640	16,988,640
Number of common stock issued for services, value	$ 300		$ 1,698
Amortization of prepaid services

Income Taxes - Results of Ope_2

Income Taxes - Results of Operations (Details Narrative)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income tax examination, description	The impact of U.S. Tax Reform primarily represents the Company's estimates of revaluing the Company's U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%
Percentage of statutory income tax rate	21.00%
Effective tax rate	0.00%	0.00%

Licenses and Supply Agreements

Licenses and Supply Agreements (Details Narrative) - Cytocom Inc., [Member]	May 01, 2018	Dec. 31, 2014
Royalty percentage		5.00%
Maximum [Member]
Royalty percentage	5.00%
Minimum [Member]
Royalty percentage	1.00%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2013	Mar. 31, 2019	Mar. 31, 2018
Rental expense		$ 5,282	$ 4,281
AHAR Pharma [Member]
Distribution agreement, description	The Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma's first-year purchase commitment.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Apr. 08, 2019
Subsequent Event [Member] | Licensing Agreement [Member]
Ownership percentage	15.57%